Cite
Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study.
MLA
Xiong, Anwen, et al. “Efficacy and Safety of KN046, a Novel Bispecific Antibody against PD-L1 and CTLA-4, in Patients with Non-Small Cell Lung Cancer Who Failed Platinum-Based Chemotherapy: A Phase II Study.” European Journal of Cancer, vol. 190, Sept. 2023, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.ejca.2023.05.024.
APA
Xiong, A., Li, W., Li, X., Fan, Y., Ma, Z., Fang, J., Xie, Q., Zhuang, W., Kang, M., Wang, J., Xu, T., Xu, M., Zhi, L., Liu, Q., Wang, N., & Zhou, C. (2023). Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study. European Journal of Cancer, 190, N.PAG. https://doi.org/10.1016/j.ejca.2023.05.024
Chicago
Xiong, Anwen, Wei Li, Xingya Li, Yun Fan, Zhiyong Ma, Jian Fang, Qiang Xie, et al. 2023. “Efficacy and Safety of KN046, a Novel Bispecific Antibody against PD-L1 and CTLA-4, in Patients with Non-Small Cell Lung Cancer Who Failed Platinum-Based Chemotherapy: A Phase II Study.” European Journal of Cancer 190 (September): N.PAG. doi:10.1016/j.ejca.2023.05.024.